<DOC>
	<DOCNO>NCT01936844</DOCNO>
	<brief_summary>Anakinra ADHF double-blind randomize clinical trial anakinra , recombinant human interleukin-1 receptor blocker , placebo patient acute decompensated heart failure aim quench acute inflammatory response , measure area-under-the-curve C reactive protein 14 day .</brief_summary>
	<brief_title>Interleukin ( IL ) -1 Blockade Acute Heart Failure ( Anakinra ADHF )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>All 5 criterion need meet enrollment patient study 1 . Primary diagnosis acute decompensated heart failure within last 24 hour evidence follow : 1. dyspnea respiratory distress tachypnea rest minimal exertion 2. evidence elevate cardiac filling pressure pulmonary congestion ( least one condition must meet ) ; i. pulmonary congestion/edema physical exam OR chest xray ; ii . plasma Brain Natriuretic Peptide ( BNP ) level ≥200 pg/mL ; iii.invasive measurement leave ventricular enddiastolic pressure &gt; 18 mmHg pulmonary artery occluding pressure ( wedge ) &gt; 16 mmHg . 2 . Left ventricular systolic dysfunction ( LVEF &lt; 40 % ) index hospitalization prior 12 month . 3 . Age ≥18 year old 4 . Willing able provide write informed consent . 5 . Screening plasma Creactive protein level &gt; 5 mg/L . Exclusion Criteria Subjects eligible meet follow 15 exclusion criterion . 1 . The primary diagnosis admission NOT decompensated heart failure , include diagnosis acute coronary syndrome , hypertensive urgency/emergency , tachy bradyarrhythmias . 2 . Concomitant clinically significant comorbidities would interfere execution interpretation study include limited acute coronary syndrome , uncontrolled hypertension orthostatic hypotension , tachy bradyarrhythmias , acute chronic pulmonary disease neuromuscular disorder affect respiration . 3 . Recent ( previous 3 month ) plan cardiac resynchronization therapy ( CRT ) , coronary artery revascularization procedure , heart valve surgery . 4 . Previous planned implantation leave ventricular assist device hearttransplant . 5 . Chronic use intravenous inotropes . 6 . Recent ( &lt; 14 day ) use immunosuppressive antiinflammatory drug ( include NonSteroidal AntiInflammatory Drugs [ NSAIDs ] ) . 7 . Chronic inflammatory disorder ( include limit rheumatoid arthritis , systemic lupus erythematosus ) . 8 . Active infection ( type ) ; 9 . Chronic/recurrent infectious disease ( include Hepatitis B virus [ HBV ] , Hepatitis C virus [ HCV ] , HIV/AIDS ) . 10 . Prior ( within past 10 year ) current malignancy . 11 . Any comorbidity limit survival ability complete study . 12 . End stage kidney disease require renal replacement therapy . 13 . Neutropenia ( &lt; 2,000/mm3 ) Thrombocytopenia ( &lt; 50,000/mm3 ) . 14 . Pregnancy . 15 . Angina , arrhythmia , electrocardiograph ( ECG ) change limit maximum exertion cardiopulmonary exercise testing obtain baseline testing .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>